Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial.
Study Goal
The researchers aimed to evaluate the anti-obesity effects of a combination of glucosyl hesperidin (G-hesperidin) and caffeine on body fat and serum triglycerides in healthy subjects with moderately high BMI and serum TG.
Results Summary
The study found that G-hesperidin combined with 50 or 75 mg of caffeine significantly reduced abdominal fat area (especially subcutaneous fat) and BMI compared to placebo, with effects increasing dose-dependently. However, the combination had no significant effect on serum TG levels.
Population
Healthy subjects with moderately high BMI (24-30 kg/m²) and serum TG (100-250 mg/dl).
Effective Dosage
500 mg G-hesperidin daily with 25, 50, or 75 mg caffeine, or placebo.
Duration
12 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
glucosyl hesperidin (G-hesperidin) plus caffeine | decrease | body fat | mice | - | reduces accumulation | #1 |
G-hesperidin | no change | high-fat diet-induced obesity | mice | - | shows little effect | #2 |
caffeine | no change | high-fat diet-induced obesity | mice | - | shows little effect | #3 |
G-hesperidin with 50-mg caffeine | decrease | abdominal fat area (AFA) | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | -8.4 ± 21.9 v.s. 16.3 ± 34.1 cm(2) | decreases were significantly greater | #4 |
G-hesperidin with 50-mg caffeine | decrease | subcutaneous fat area (SFA) | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | -9.3 ± 17.1 v.s. 11.2 ± 18.3 cm(2) | decreases were significantly greater | #5 |
G-hesperidin with 75-mg caffeine | decrease | abdominal fat area (AFA) | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | -17.0 ± 31.4 v.s. 16.3 ± 34.1 cm(2) | decreases were significantly greater | #6 |
G-hesperidin with 75-mg caffeine | decrease | subcutaneous fat area (SFA) | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | -12.4 ± 18.7 v.s. 11.2 ± 18.3 cm(2) | decreases were significantly greater | #7 |
G-hesperidin | increase | fat-decreasing effects | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | - | Fat-decreasing effects were enhanced dose-dependently | #8 |
G-hesperidin with 75-mg caffeine | decrease | BMI | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | -0.56 ± 0.74 v.s. -0.02 ± 0.58 kg/m(2) | decreases were significantly greater | #9 |
G-hesperidin with/without caffeine | no change | serum TG | healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) | - | had no effect | #10 |
BACKGROUND: We have previously shown that a combination of glucosyl hesperidin (G-hesperidin) plus caffeine reduces accumulation of body fat, whereas G-hesperidin or caffeine alone shows little effect on high-fat diet-induced obesity in mice. The aim of this study is to evaluate the anti-obesity effect of G-hesperidin plus caffeine on body fat and serum TG in healthy subjects with moderately high body mass index (BMI) and serum TG. Since we considered that there are individual differences in caffeine sensitivity, we conducted dose-finding study of caffeine combined with G-hesperidin. METHODS: Seventy-five healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) were divided and assigned to 12-week intervention with daily intakes of 500 mg of G-hesperidin with or without 25, 50, or 75 mg of caffeine, or placebo in a randomized double-blind placebo-controlled design . RESULTS: After intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1 cm(2); p < 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3 cm(2); p < 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1 cm(2); p < 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3 cm(2); p < 0.01) than in the placebo group. Fat-decreasing effects of G-hesperidin were enhanced dose-dependently by caffeine addition. BMI decreases were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group (-0.56 ± 0.74 v.s. -0.02 ± 0.58 kg/m(2); p < 0.05). G-hesperidin with/without caffeine had no effect on serum TG (p > 0.05 v.s. placebo). CONCLUSIONS: These data suggested that a combination of 500-mg G-hesperidin with 50- or 75-mg caffeine may be useful for the prevention or treatment of obesity. TRIAL REGISTRATION: UMIN Clinical Trials Registry 000019241 .